Advarra, the market leader in regulatory reviews and a leading provider of clinical research technology, today announced the ...

Gemini normalized the inflammatory response at the cellular level in stage 3 and 4 CKD patients – – Gemini could potentially ...

LabConnect, a leading global provider of central laboratory services today announced plans to form a strategic collaboration ...

The platform’s architecture allows it to handle everything from small single-site pilot trials to complex multi-phase ...

Generative artificial intelligence (AI) has absolutely exploded onto the scene. It's become a top strategic priority in the ...

ABBOTT PARK, Ill., April 26, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) has announced new data from its Volt CE Mark Study that show strong safety and efficacy out to 12 months for patients receiving ...

As previously reported, 15 out of 16 (94%) patients in Phase 2b in the Per Protocol Population experienced Clinical Cure (CC) and all 15 of 15 (100%) remained free of C. difficile infection (CDI) ...

Idiopathic normal-pressure hydrocephalus is a neurologic disorder characterized by impaired gait, balance, cognition, and ...

Mayo Clinic researchers have developed a new way to predict whether existing drugs could be repurposed to treat heart failure ...

Pfizer (PFE) and Moderna (MRNA) reveal trial data showing their updated COVID mRNA vaccines are safe and effective after ...